This biomarker is also known as:
- CUB domain-containing protein 1,
- membrane glycoprotein gp140,
- transmembrane and associated with src kinases,
- subtractive immunization M plus HEp3-associated 135 kDa protein,
- Membrane glycoprotein gp140,
- CUB domain containing protein 1,
- Subtractive immunization M plus HEp3-associated 135 kDa protein,
- CD318 antigen,
- Transmembrane and associated with src kinases,
View in BioMuta
CDCP1 is a transmembrane protein containing three extracellular CUB domains. It is found to be overexpressed in colon and lung cancers. Its expression level is correlated with the metastatic ability of carcinoma cells. CDCP1 is located on the cell surface and may be involved in cell adhesion and cell matrix association. Alternatively spliced transcript variants encoding distinct isoforms have been reported.
There are no datasets associated with this biomarker.
The following organs have data associated with this biomarker…
CDCP1 is a transmembrane tumor vascular marker (TVM) that is selectively expressed in tumor vasculature and represents a promising target for vascular imaging or anti-vascular therapy of epithelial ovarian cancer.
CDCP1 was one of 13 genes out of 50 selected for further validation in PMID:21617380. Average expression of CDCP1 was significantly higher in epithelial ovarian cancer tumors than any other normal tissue tested.
This biomarker is currently being annotated or is under review.
You must be logged in
or do not have permission to view any additional information. Contact Heather Kincaid at
if you should have access to this biomarker.
Update: Pre-application webinar information now available.
The National Cancer Institute's Division of Cancer Prevention has released a new funding opportunity to solicit organ-specific applications for Biomarker Developmental Laboratories (BDLs), one of the four scientific units of the recently funded Early Detection Research Network (EDRN). The EDRN is a national infrastructure funded to discover, develop, and validate biomarkers for risk assessment, detection, and molecular diagnosis and prognosis of early cancer. BDLs are responsible for the discovery, development, characterization, and testing of new, or the refinement of existing, biomarkers and biomarker assays for risk assessment, detection, and molecular diagnosis and prognosis of cancers.
The existing BDLs are primarily focused on ovary and gastrointestinal cancers. The proposed BDLs (to be supported under this funding opportunity) should be focused on one or more of the following cancers: breast, prostate and other genitourinary organs, or lung. In addition, cancers with rapidly rising incidence rates, e.g., endometrial, hepatocellular, kidney, thyroid, oropharyngeal cancers, and/or cancers with unique etiology, e.g., mesothelioma, will be considered.
The newly funded units of the Early Detection Research Network will be announced later in April. Successful applicants have already been notified. Those researchers who were not successful during the last round of applications are encouraged to apply to this opportunity.